Dual functional novel peptide having cell permeability and bone tissue regeneration ability, and use thereof

Patent metadata

Field	Value
Publication number	US-2019382446-A1
Application number	US-201716464099-A
Country	US
Kind code	A1
Filing date	Dec 27, 2017
Priority date	Dec 27, 2016
Publication date	Dec 19, 2019
Grant date	—

Abstract

The present invention relates to a novel peptide derived from the copine 7 protein and having both cell permeability and bone tissue regeneration ability, and to a use of the peptide. The peptide according to the present invention has excellent bone tissue regeneration ability and is therefore useful for treating a disease requiring bone regeneration, such as osteoporosis. Particularly, by also having cell permeability, the peptide does not require the attachment of a separate peptide or addition of another preparation for the cell permeation thereof and thus can be conveniently applied in orthopedics and the like requiring various surgical regeneration treatments.

First claim

1 . A peptide set forth in the amino acid sequence of SEQ ID NO: 4.

2 . The peptide according to claim 1 , wherein the peptide has dual functions of cell permeability and bone tissue regeneration ability.

3 . A method for regenerating bone tissue, the method comprising administering a pharmaceutical composition comprising the peptide according to claim 1 or grafting a biomaterial comprising the peptide according to claim 1 to a subject in need of bone tissue regeneration.

4 . The method according to claim 3 , wherein the composition is formulated as the one selected from the group consisting of a formulation for oral administration, a formulation for injection, and a gel formulation for topical implantation.

5 . The method according to claim 4 , wherein the gel formulation for topical implantation comprises:
i) a synthetic polymer selected from the group consisting of polylactic glycolic acid, a poloxamer and propylene glycol; or ii) a natural polymer selected from the group consisting of collagen, alginic acid, propylene glycol alginate, chondroitin sulfate and chitosan.

6 . The method according to claim 3 , wherein the composition is administered at a dose of 1 to 60 mg per 1 kg of a body weight of a subject in need of treatment.

7 . A biomaterial comprising the peptide according to claim 1 .

8 . The biomaterial according to claim 7 , wherein the bio-material is selected from the group consisting of a natural polymer, a bone mineral and a synthetic polymer.

9 . The biomaterial according to claim 8 , wherein the natural polymer is selected from the group consisting of collagen, alginic acid, propylene glycol, chondroitin sulfate and chitosan.

10 . The biomaterial according to claim 8 , wherein the bone mineral is i) derived from an animal or ii) chemically synthesized.

11 . The biomaterial according to claim 10 , wherein the chemically synthesized bone mineral is hydroxyapatite.

12 . The biomaterial according to claim 8 , wherein the synthetic polymer is selected from the group consisting of polylactic glycolic acid, a poloxamer and propylene glycol.

13 . (canceled)

Assignees

• Seoul Nat Univ R&Db Foundation
• Nano Intelligent Biomedical Eng Corporation Co Ltd

Inventors

• Park Yoon Jeong
• Chung Chong-Pyoung
• Lee Jue-Yeon
• Park Joocheol

Classifications

• A61L2430/02

  for reconstruction of bones; weight-bearing implants · CPC title

• A61K9/0014

  Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00) · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• C07K2319/00

  Fusion polypeptide · CPC title

• A61L27/22

  Polypeptides or derivatives thereof {, e.g. degradation products} · CPC title